SPRO (Spero Therapeutics) Change In Inventory: $0.00 Mil (TTM As of Mar. 2026)

What is Spero Therapeutics Change In Inventory?

Spero Therapeutics SPRO -0.90% 55 Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Spero Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Spero Therapeutics's inventory stayed the same from Dec. 2025 to Mar. 2026 .

Spero Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Spero Therapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Spero Therapeutics's Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Spero Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

Spero Therapeutics (NAS:SPRO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Spero Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Spero Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Spero Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.258
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Change In Inventory Related Terms

Spero Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Change In Inventory can be seen below:

Spero Therapeutics Change In Inventory Chart

Spero Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Inventory

Get a 7-Day Free Trial

0.00

Spero Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Change In Inventory	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

55GF Score

Spero Therapeutics Inc SPRO

Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Spero Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Change In Inventory →

What does a Change In Inventory of $0.00 Mil mean?

Spero Therapeutics (SPRO) has a Change In Inventory of $0.00 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Spero Therapeutics and its competitors.

Is Spero Therapeutics' Change In Inventory too high?

Spero Therapeutics' current Change In Inventory is $0.00 Mil. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Spero Therapeutics' Change In Inventory compare to VXRT and ADCT?

Spero Therapeutics' Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Inventory for a Biotechnology company?

A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Inventory mean?

A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Spero Therapeutics and its competitors. Spero Therapeutics's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Spero Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $2.19 — trading 108.1% above its estimated fair value. The current Change In Inventory is $0.00 Mil. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Inventory calculated?

Change In Inventory is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.19 is trading 108.1% above its estimated GF Value™ of $1.05. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

Change In Inventory: $0.00 Mil
GF Value™: $1.05 vs. price of $2.19 (108.1% above fair value)
GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies VXRT ADCT GNLX COYA AGEN VTVT LIXT SMNR CNTB ENLV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 2HA:Germany

Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

55GF Score

Get the complete analysis for SPRO

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.19

Price

$1.05

GF Value

View SPRO Analysis

See Change In Inventory data for all stocks →